24-570 Phase I
A Phase 1a/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer
Search Cancer Clinical Trials
Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
100 results
21-398 Phase I
A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
24-353 Phase I
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
24-649 Phase I
A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant Solid Tumors
24-514 Phase I
A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)
25-099 Phase I
A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure
25-370 Phase I
A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator’s Choice of Adjuvant Chemotherapy in Participants with Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
23-369 Phase I
A Phase 1b, Open-Label Study of Elranatamab in combination with Carzfilzomib plus Dexamethasone and Elranatmab in combination with PF-0790180 in Participants with relapsed refractory Multiple Myeloma
22-448 Phase II
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
22-008 Phase II
A phase 1b/2 study of onvansertib in combination with paclitaxel in triple-negative metastatic breast cancer patients
Showing 1 - 10 of 100 results